Cognitive burden of common non-antiretroviral medications in HIV-infected women

Leah H. Rubin, Kendra K. Radtke, Seenae Eum, Bani Tamraz, Krithika N. Kumanan, Gayle Springer, Pauline M. Maki, Kathryn Anastos, Daniel Merenstein, Roksana Karim, Kathleen M. Weber, Deborah Gustafson, Ruth M. Greenblatt, Jeffrey R. Bishop

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Objective: The aging HIV population has increased comorbidity burden and consequently non-antiretroviral medication utilization. Many non-antiretroviral medications have known neurocognitive-adverse effects ("NC-AE medications"). We assessed the cognitive effects of NC-AE medications in HIV+ and HIV-women. Methods: One thousand five hundred fifty-eight participants (1037 HIV+; mean age 46) from the Women's Interagency HIV Study completed a neuropsychological test battery between 2009 and 2011. The total number of NC-AE medications and subgroups (eg, anticholinergics) were calculated based on self-report. Generalized linear models for non-normal data were used to examine the cognitive burden of medications and factors that exacerbate these effects. Results: HIV+ women reported taking more NC-AE medications vs. HIV-women (P < 0.05). NC-AE medication use altogether was not associated with cognitive performance. However, among NC-AE medication subgroups, anticholinergic-acting medications, but not opioids or anxiolytics/anticonvulsants, were negatively associated with performance. HIV status moderated the association between these NC-AE medication subgroups and performance (P's < 0.05). HIV-serostatus differences (HIV-< HIV+) in global, learning, fluency, and motor function were greatest among women taking >1 anticholinergic medications. HIV-serostatus differences in performance on learning and psychomotor speed were also greatest among women taking 1 or more anxiolytics/anticonvulsants and 1 or more opioids, respectively. Conclusions: HIV+ women have increased cognitive vulnerabilities to anticholinergic, anxiolytic/anticonvulsant, and opioid medications. Potential synergy between these medications and HIV may explain some HIV-related cognitive impairments. It may be important clinically to consider these specific types of medications as a contributor to impaired cognitive performance in HIV+ women and assess the cost/benefit of treatment dosage for underlying conditions.

Original languageEnglish (US)
Pages (from-to)83-91
Number of pages9
JournalJournal of Acquired Immune Deficiency Syndromes
Volume79
Issue number1
DOIs
StatePublished - Sep 1 2018

Fingerprint

HIV
Cholinergic Antagonists
Anti-Anxiety Agents
Anticonvulsants
Opioid Analgesics
Nonlinear Dynamics
Neuropsychological Tests
Self Report
Cost-Benefit Analysis
Comorbidity
Learning
Population

Keywords

  • anticholinergic
  • cognition
  • HIV
  • women

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)

Cite this

Rubin, L. H., Radtke, K. K., Eum, S., Tamraz, B., Kumanan, K. N., Springer, G., ... Bishop, J. R. (2018). Cognitive burden of common non-antiretroviral medications in HIV-infected women. Journal of Acquired Immune Deficiency Syndromes, 79(1), 83-91. https://doi.org/10.1097/QAI.0000000000001755

Cognitive burden of common non-antiretroviral medications in HIV-infected women. / Rubin, Leah H.; Radtke, Kendra K.; Eum, Seenae; Tamraz, Bani; Kumanan, Krithika N.; Springer, Gayle; Maki, Pauline M.; Anastos, Kathryn; Merenstein, Daniel; Karim, Roksana; Weber, Kathleen M.; Gustafson, Deborah; Greenblatt, Ruth M.; Bishop, Jeffrey R.

In: Journal of Acquired Immune Deficiency Syndromes, Vol. 79, No. 1, 01.09.2018, p. 83-91.

Research output: Contribution to journalArticle

Rubin, LH, Radtke, KK, Eum, S, Tamraz, B, Kumanan, KN, Springer, G, Maki, PM, Anastos, K, Merenstein, D, Karim, R, Weber, KM, Gustafson, D, Greenblatt, RM & Bishop, JR 2018, 'Cognitive burden of common non-antiretroviral medications in HIV-infected women', Journal of Acquired Immune Deficiency Syndromes, vol. 79, no. 1, pp. 83-91. https://doi.org/10.1097/QAI.0000000000001755
Rubin, Leah H. ; Radtke, Kendra K. ; Eum, Seenae ; Tamraz, Bani ; Kumanan, Krithika N. ; Springer, Gayle ; Maki, Pauline M. ; Anastos, Kathryn ; Merenstein, Daniel ; Karim, Roksana ; Weber, Kathleen M. ; Gustafson, Deborah ; Greenblatt, Ruth M. ; Bishop, Jeffrey R. / Cognitive burden of common non-antiretroviral medications in HIV-infected women. In: Journal of Acquired Immune Deficiency Syndromes. 2018 ; Vol. 79, No. 1. pp. 83-91.
@article{fc023efb45a3435d9ad4374e4c0ae436,
title = "Cognitive burden of common non-antiretroviral medications in HIV-infected women",
abstract = "Objective: The aging HIV population has increased comorbidity burden and consequently non-antiretroviral medication utilization. Many non-antiretroviral medications have known neurocognitive-adverse effects ({"}NC-AE medications{"}). We assessed the cognitive effects of NC-AE medications in HIV+ and HIV-women. Methods: One thousand five hundred fifty-eight participants (1037 HIV+; mean age 46) from the Women's Interagency HIV Study completed a neuropsychological test battery between 2009 and 2011. The total number of NC-AE medications and subgroups (eg, anticholinergics) were calculated based on self-report. Generalized linear models for non-normal data were used to examine the cognitive burden of medications and factors that exacerbate these effects. Results: HIV+ women reported taking more NC-AE medications vs. HIV-women (P < 0.05). NC-AE medication use altogether was not associated with cognitive performance. However, among NC-AE medication subgroups, anticholinergic-acting medications, but not opioids or anxiolytics/anticonvulsants, were negatively associated with performance. HIV status moderated the association between these NC-AE medication subgroups and performance (P's < 0.05). HIV-serostatus differences (HIV-< HIV+) in global, learning, fluency, and motor function were greatest among women taking >1 anticholinergic medications. HIV-serostatus differences in performance on learning and psychomotor speed were also greatest among women taking 1 or more anxiolytics/anticonvulsants and 1 or more opioids, respectively. Conclusions: HIV+ women have increased cognitive vulnerabilities to anticholinergic, anxiolytic/anticonvulsant, and opioid medications. Potential synergy between these medications and HIV may explain some HIV-related cognitive impairments. It may be important clinically to consider these specific types of medications as a contributor to impaired cognitive performance in HIV+ women and assess the cost/benefit of treatment dosage for underlying conditions.",
keywords = "anticholinergic, cognition, HIV, women",
author = "Rubin, {Leah H.} and Radtke, {Kendra K.} and Seenae Eum and Bani Tamraz and Kumanan, {Krithika N.} and Gayle Springer and Maki, {Pauline M.} and Kathryn Anastos and Daniel Merenstein and Roksana Karim and Weber, {Kathleen M.} and Deborah Gustafson and Greenblatt, {Ruth M.} and Bishop, {Jeffrey R.}",
year = "2018",
month = "9",
day = "1",
doi = "10.1097/QAI.0000000000001755",
language = "English (US)",
volume = "79",
pages = "83--91",
journal = "Journal of Acquired Immune Deficiency Syndromes",
issn = "1525-4135",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Cognitive burden of common non-antiretroviral medications in HIV-infected women

AU - Rubin, Leah H.

AU - Radtke, Kendra K.

AU - Eum, Seenae

AU - Tamraz, Bani

AU - Kumanan, Krithika N.

AU - Springer, Gayle

AU - Maki, Pauline M.

AU - Anastos, Kathryn

AU - Merenstein, Daniel

AU - Karim, Roksana

AU - Weber, Kathleen M.

AU - Gustafson, Deborah

AU - Greenblatt, Ruth M.

AU - Bishop, Jeffrey R.

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Objective: The aging HIV population has increased comorbidity burden and consequently non-antiretroviral medication utilization. Many non-antiretroviral medications have known neurocognitive-adverse effects ("NC-AE medications"). We assessed the cognitive effects of NC-AE medications in HIV+ and HIV-women. Methods: One thousand five hundred fifty-eight participants (1037 HIV+; mean age 46) from the Women's Interagency HIV Study completed a neuropsychological test battery between 2009 and 2011. The total number of NC-AE medications and subgroups (eg, anticholinergics) were calculated based on self-report. Generalized linear models for non-normal data were used to examine the cognitive burden of medications and factors that exacerbate these effects. Results: HIV+ women reported taking more NC-AE medications vs. HIV-women (P < 0.05). NC-AE medication use altogether was not associated with cognitive performance. However, among NC-AE medication subgroups, anticholinergic-acting medications, but not opioids or anxiolytics/anticonvulsants, were negatively associated with performance. HIV status moderated the association between these NC-AE medication subgroups and performance (P's < 0.05). HIV-serostatus differences (HIV-< HIV+) in global, learning, fluency, and motor function were greatest among women taking >1 anticholinergic medications. HIV-serostatus differences in performance on learning and psychomotor speed were also greatest among women taking 1 or more anxiolytics/anticonvulsants and 1 or more opioids, respectively. Conclusions: HIV+ women have increased cognitive vulnerabilities to anticholinergic, anxiolytic/anticonvulsant, and opioid medications. Potential synergy between these medications and HIV may explain some HIV-related cognitive impairments. It may be important clinically to consider these specific types of medications as a contributor to impaired cognitive performance in HIV+ women and assess the cost/benefit of treatment dosage for underlying conditions.

AB - Objective: The aging HIV population has increased comorbidity burden and consequently non-antiretroviral medication utilization. Many non-antiretroviral medications have known neurocognitive-adverse effects ("NC-AE medications"). We assessed the cognitive effects of NC-AE medications in HIV+ and HIV-women. Methods: One thousand five hundred fifty-eight participants (1037 HIV+; mean age 46) from the Women's Interagency HIV Study completed a neuropsychological test battery between 2009 and 2011. The total number of NC-AE medications and subgroups (eg, anticholinergics) were calculated based on self-report. Generalized linear models for non-normal data were used to examine the cognitive burden of medications and factors that exacerbate these effects. Results: HIV+ women reported taking more NC-AE medications vs. HIV-women (P < 0.05). NC-AE medication use altogether was not associated with cognitive performance. However, among NC-AE medication subgroups, anticholinergic-acting medications, but not opioids or anxiolytics/anticonvulsants, were negatively associated with performance. HIV status moderated the association between these NC-AE medication subgroups and performance (P's < 0.05). HIV-serostatus differences (HIV-< HIV+) in global, learning, fluency, and motor function were greatest among women taking >1 anticholinergic medications. HIV-serostatus differences in performance on learning and psychomotor speed were also greatest among women taking 1 or more anxiolytics/anticonvulsants and 1 or more opioids, respectively. Conclusions: HIV+ women have increased cognitive vulnerabilities to anticholinergic, anxiolytic/anticonvulsant, and opioid medications. Potential synergy between these medications and HIV may explain some HIV-related cognitive impairments. It may be important clinically to consider these specific types of medications as a contributor to impaired cognitive performance in HIV+ women and assess the cost/benefit of treatment dosage for underlying conditions.

KW - anticholinergic

KW - cognition

KW - HIV

KW - women

UR - http://www.scopus.com/inward/record.url?scp=85059200396&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059200396&partnerID=8YFLogxK

U2 - 10.1097/QAI.0000000000001755

DO - 10.1097/QAI.0000000000001755

M3 - Article

C2 - 29781879

AN - SCOPUS:85059200396

VL - 79

SP - 83

EP - 91

JO - Journal of Acquired Immune Deficiency Syndromes

JF - Journal of Acquired Immune Deficiency Syndromes

SN - 1525-4135

IS - 1

ER -